Trehalose Boosts Macrophage Ability to Clear Plaques
|
By LabMedica International staff writers Posted on 22 Jun 2017 |

Image: A photomicrograph of a cross section of a mouse aorta, the main artery in the body, with a large plaque. Straight red lines toward the upper left are the wall of the aorta. Yellow areas are where housekeeping cells called macrophages are clearing cellular waste (Photo courtesy of Ismail Sergin, Washington University School of Medicine).
Cardiovascular disease researchers working with mouse models have found that treatment with the sugar trehalose boosts the activity of the macrophages responsible for clearing the molecular and cellular debris that make up atherosclerotic plaques.
Macrophages specialize in removing lipids and debris present in atherosclerotic plaques. However, as plaques grow, their size and complexity render macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysfunctional proteins and organelles. The decline in the autophagy-lysosome system that contributes to this situation is evidenced by disarray of key autophagy markers in both mouse and human atherosclerotic plaques.
Investigators at Washington University School of Medicine (St. Louis, MO, USA) reported that by boosting the activity of the macrophage protein transcription factor EB (TFEB), they could reverse the autophagy dysfunction of macrophages in plaques. TFEB is known to regulate many lysosomal genes, and by translocating to the cell nucleus, TFEB itself can be activated when the lysosome malfunctions. This serves to regulate both the abundance of lysosomes found in the cell and their ability to degrade complex molecules.
The investigators described in the June 7, 2017, online edition of the journal Nature Communications the ability of the natural sugar trehalose to act as an inducer of macrophage autophagy-lysosomal biogenesis and demonstrated the ability of trehalose to stimulate the plaque clearing properties of macrophage TFEB overexpression.
Trehalose is a non-reducing natural disaccharide (alpha,alpha-1,1-glucoside) synthesized endogenously by non-mammalian organisms such as insects, crustaceans, and certain plants. Present in high concentration in these organisms, trehalose is thought to provide protection against environmental stresses such as osmotic and temperature shocks by stabilizing biomolecules. The pharmaceutical industry uses trehalose as a stabilizer in numerous medicines. In the food industry, trehalose has been used as a sweetener because of its mild sweetness as compared to its other closely related non-reducing disaccharide sucrose. Owing to the ability of trehalose to induce autophagy and ameliorate various protein aggregation neurodegenerative diseases and the finding of TFEB as an autophagy inducer particularly of protein aggregates, the investigators became interested in evaluating the effects of trehalose in the induction of macrophage TFEB, autophagy-lysosomal biogenesis, and atherosclerosis.
Toward this end, they injected mice prone to atherosclerosis with trehalose. Following treatment, these animals displayed reduced plaque in their arteries. The sizes of the plaques measured in the aortic root were variable, but on average, the plaques measured 0.35 square millimeters in control mice compared with 0.25 square millimeters in the mice receiving trehalose, which translated into a roughly 30% decrease in plaque size. The effect disappeared when the mice were given trehalose orally or when they were injected with other types of sugar, even those with similar structures.
"We are interested in enhancing the ability of these immune cells, called macrophages, to degrade cellular garbage - making them super-macrophages," said senior author Dr. Babak Razani, assistant professor of medicine at Washington University School of Medicine. "In atherosclerosis, macrophages try to fix damage to the artery by cleaning up the area, but they get overwhelmed by the inflammatory nature of the plaques. Their housekeeping process gets gummed up. So their friends rush in to try to clean up the bigger mess and also become part of the problem. A soup starts building up - dying cells, more lipids. The plaque grows and grows."
"Trehalose is not just enhancing the housekeeping machinery that is already there," said Dr. Razani. "It is triggering the cell to make new machinery. This results in more autophagy - the cell starts a degradation fest. Is this the only way that trehalose works to enhance autophagy by macrophages? We cannot say that for sure - we are still testing that. But is it a predominant process? Yes."
Related Links:
Washington University School of Medicine
Macrophages specialize in removing lipids and debris present in atherosclerotic plaques. However, as plaques grow, their size and complexity render macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysfunctional proteins and organelles. The decline in the autophagy-lysosome system that contributes to this situation is evidenced by disarray of key autophagy markers in both mouse and human atherosclerotic plaques.
Investigators at Washington University School of Medicine (St. Louis, MO, USA) reported that by boosting the activity of the macrophage protein transcription factor EB (TFEB), they could reverse the autophagy dysfunction of macrophages in plaques. TFEB is known to regulate many lysosomal genes, and by translocating to the cell nucleus, TFEB itself can be activated when the lysosome malfunctions. This serves to regulate both the abundance of lysosomes found in the cell and their ability to degrade complex molecules.
The investigators described in the June 7, 2017, online edition of the journal Nature Communications the ability of the natural sugar trehalose to act as an inducer of macrophage autophagy-lysosomal biogenesis and demonstrated the ability of trehalose to stimulate the plaque clearing properties of macrophage TFEB overexpression.
Trehalose is a non-reducing natural disaccharide (alpha,alpha-1,1-glucoside) synthesized endogenously by non-mammalian organisms such as insects, crustaceans, and certain plants. Present in high concentration in these organisms, trehalose is thought to provide protection against environmental stresses such as osmotic and temperature shocks by stabilizing biomolecules. The pharmaceutical industry uses trehalose as a stabilizer in numerous medicines. In the food industry, trehalose has been used as a sweetener because of its mild sweetness as compared to its other closely related non-reducing disaccharide sucrose. Owing to the ability of trehalose to induce autophagy and ameliorate various protein aggregation neurodegenerative diseases and the finding of TFEB as an autophagy inducer particularly of protein aggregates, the investigators became interested in evaluating the effects of trehalose in the induction of macrophage TFEB, autophagy-lysosomal biogenesis, and atherosclerosis.
Toward this end, they injected mice prone to atherosclerosis with trehalose. Following treatment, these animals displayed reduced plaque in their arteries. The sizes of the plaques measured in the aortic root were variable, but on average, the plaques measured 0.35 square millimeters in control mice compared with 0.25 square millimeters in the mice receiving trehalose, which translated into a roughly 30% decrease in plaque size. The effect disappeared when the mice were given trehalose orally or when they were injected with other types of sugar, even those with similar structures.
"We are interested in enhancing the ability of these immune cells, called macrophages, to degrade cellular garbage - making them super-macrophages," said senior author Dr. Babak Razani, assistant professor of medicine at Washington University School of Medicine. "In atherosclerosis, macrophages try to fix damage to the artery by cleaning up the area, but they get overwhelmed by the inflammatory nature of the plaques. Their housekeeping process gets gummed up. So their friends rush in to try to clean up the bigger mess and also become part of the problem. A soup starts building up - dying cells, more lipids. The plaque grows and grows."
"Trehalose is not just enhancing the housekeeping machinery that is already there," said Dr. Razani. "It is triggering the cell to make new machinery. This results in more autophagy - the cell starts a degradation fest. Is this the only way that trehalose works to enhance autophagy by macrophages? We cannot say that for sure - we are still testing that. But is it a predominant process? Yes."
Related Links:
Washington University School of Medicine
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








